Drug Trial Radar · NCT03945513
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles
Last checked: Nov 20, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,034
Actual
Start
Dec 3, 2019
Primary completion
Jun 30, 2023
Study completion Sep 8, 2023
Sponsor
- Lead sponsor
- Insud PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Chemo Research
- First posted
- May 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 13 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this trial is to demonstrate the contraceptive efficacy of LPRI424, Additional goals of the trial are to demonstrate the safety and tolerability of LPRI424.
Conditions
- Contraception
Interventions
LPRI424 (dienogest/ethinylestradiol)Drug
One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of pregnancies (evaluable cycles)Time frame: up to 13 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fellows Research Alliance, Inc.
Savannah, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.